One analysis used medical and pharmacy claims data to evaluate outcomes in 371,698 patients with type 2 diabetes initiating GLP-1 RA, SGLT2i, DPP-4i and sulfonylurea class medications, with the primary outcome being time-to-treatment for DME or PDR
Body composition: Regular measurements (weight, body fat percentage, waist circumference) provide objective feedback
A shunt counts the actual energy flowing in and out (Coulomb counting), which is far more accurate than voltage sensing alone
In part because of off-label uses, or using drugs for purposes that are not FDA-approved, there have been intermittent global shortages of Novo Nordisks Type 2 diabetes drugs Ozempic and Rybelsus as people have sought them for weight loss
I appreciate the discussion on the #microdosing trend surrounding GLP1 medications
B12 addresses the fatigue many GLP-1 patients experience